Daniel J. Deangelo
Associate Professor
Hematologic OncologyÂ
Dana-Farber Cancer Institute
United States of America
Biography
Dr. DeAngelo received his MD and PhD from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.
Research Interest
Hematologic Oncology
Publications
-
DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T et al (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 8 :1628-1636.
-
DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C et al (2013) Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 3 :326-35.
-
Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M et al (2014) A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res 4 :430-434.
